Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate [...]
There’s a better way to do a PET scan, by using radiotracer fluciclovine (fluorine-18; F-18) (Journal of Nuclear Medicine, March 2017) According to researcher Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, fluciclovine can improve imaging in recurrent prostate cancer patients with no additional radiation side effects. An improved PET [...]
There's a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer. Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone. Todays testosterone reducing therapies require injections and [...]
Here is a newly emerged advocacy opportunity regarding the PSA test and Prostate Cancer in the USA. Malecare feels you should be empowered to participate in this national health policy issue. CMS' Center for Medicare issued what is known as a Medicare Advantage Call letter. In the letter, the CMS signals to Medicare Advantage Plans [...]
Men living in wealthier zip codes in the United States live longer with advanced prostate cancer than men in lower income zip codes. Creighton University, Omaha, NE researchers studied income levels and overall survival of men diagnosed with stage IV prostate cancer. Lead author Sabra Ahmed and his team looked at 50,639 men in the National Cancer Database diagnosed [...]